Tempus AI vs. Butterfly: Which AI Health Tech Stock is the Better Buy?

Tempus AI (TEM) and Butterfly Network (BFLY), two AI-driven healthcare companies, have significantly outperformed the market, with shares surging 55.4% and 114.8% respectively over the past year. While Tempus AI shows promise with strong revenue growth, margin expansion, and strategic partnerships, Butterfly Network is considered a more compelling near-term investment due to its improving financials, lower valuation, and a higher average target price suggesting a better upside of 94.86% compared to Tempus AI's 10.55%.

Analysis

Tempus AI (TEM) and Butterfly Network (BFLY) have demonstrated significant market outperformance over the past year, with share price increases of 55.4% and 114.8% respectively, substantially exceeding gains in the broader Medical Info Systems industry (13.6%) and the S&P 500 (10.8%). Tempus AI exhibits robust fundamental strength, evidenced by a 75.4% year-over-year revenue surge in Q1 2025, partly driven by a 58% growth in its high-margin data licensing business, and is on a clear trajectory toward adjusted EBITDA profitability in 2025, having narrowed its Q1 adjusted EBITDA loss to $16.2 million from $43.9 million a year earlier. Furthermore, TEM's $200 million, three-year AI partnership with AstraZeneca and Pathos, alongside a contract backlog exceeding $1 billion, underpins future revenue visibility. Butterfly Network, while showing more modest Q1 2025 revenue growth of 20% year-over-year, has achieved notable gross margin expansion to 63% and a reduction in its adjusted EBITDA loss to $9.1 million, supported by a successful $81 million capital raise and disciplined operating expenses leading to a normalized cash burn of $6.7 million. BFLY's valuation appears more favorable, with a forward price-to-sales ratio of 5.00, below TEM's 7.90 and the industry average of 5.51X. Analyst price targets also suggest a significantly larger upside potential for BFLY at 94.86%, compared to 10.55% for TEM, leading to its current Zacks Rank #2 (Buy) versus TEM's Zacks Rank #3 (Hold).

Key Decisions for Investors

• The provided analysis suggests Butterfly Network (BFLY) presents a more compelling near-term investment case, primarily due to its attractive valuation relative to Tempus AI and the industry, improving financial metrics including gross margin expansion, and significantly higher analyst-projected upside.
• Investors should closely monitor Tempus AI's (TEM) progress towards its stated goal of achieving adjusted EBITDA profitability in 2025 and the successful execution of its substantial contract backlog, which are key to validating its long-term growth narrative in precision oncology.
• Key factors to watch for Butterfly Network include its ability to sustain recent gross margin improvements, manage operating expenses and cash burn effectively post-capital raise, and navigate international market dynamics, particularly the impact of USAID funding delays on its global health segment.